Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News ResMed study shows benefits of ASV therapy for sleep apnoea

ResMed study shows benefits of ASV therapy for sleep apnoea

22nd March 2017

ResMed has announced the publication of a new study showing the benefits of adaptive servo-ventilation (ASV) therapy in treating obstructive or central sleep apnoea.

The research, published in the Journal of the American College of Cardiology, investigated whether treatment of moderate to severe sleep-disordered breathing with ASV therapy could improve cardiovascular outcomes in patients hospitalised for a sudden worsening of their heart failure over six months.

A statistically significant improvement was seen in cardiovascular outcomes, including freedom from cardiovascular hospitalisation and improvements in functional capacity, when ASV therapy was used.

It shows that this form of treatment could be a promising new option for heart failure patients with preserved ejection fraction and sleep apnoea.

Dr Carlos Nunez, ResMed's chief medical officer, said: "I hope future studies can further establish these benefits and lead to life-improving treatment recommendations for countless patients with sleep apnoea."

This comes after the firm was recently recognised as a global leader in remote patient monitoring in a report compiled by Berg Insight.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801833822-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.